Fusiderm B is a topical medication that combines two active ingredients-Fusidic Acid (2 %) and Betamethasone (0.12 %). It is supplied in a tube formulation intended for external use on the skin. The product belongs to the therapeutic categories of pain relief and skin care, addressing inflammatory skin conditions that are complicated by bacterial infection. In Hong Kong, Fusiderm B is classified as a prescription-only (Rx) preparation and is regulated by the Department of Health (Food and Environmental Hygiene Department).
Fusidic Acid is a steroid-derived antibiotic that exerts its effect by inhibiting bacterial protein synthesis. It binds to the elongation factor G (EF-G) on the bacterial ribosome, preventing translocation of the growing peptide chain and thereby halting bacterial growth. This activity is primarily effective against Gram-positive organisms such as Staphylococcus aureus.
Betamethasone is a potent synthetic corticosteroid. It diffuses across cell membranes and binds to intracellular glucocorticoid receptors, leading to changes in gene transcription. The resultant actions include:
When applied together, Fusidic Acid targets the infecting bacteria while Betamethasone reduces the accompanying inflammation, redness, itching, and pain. The combination can thus provide faster symptomatic relief compared with using either agent alone.
Fusiderm B is approved in Hong Kong for the topical treatment of uncomplicated bacterial skin infections that have an inflammatory component, such as:
The product is intended for adults and children over 12 years of age. Use on extensive body surface areas or on broken skin that may permit systemic absorption should be avoided unless directed by a healthcare professional.
Current peer-reviewed literature does not provide strong evidence for routine off-label applications of Fusiderm B. Therefore, no off-label uses are presented in this article.
If you are taking other prescription or over-the-counter medications, inform your healthcare provider before starting Fusiderm B.
Standard dosing: Apply a thin layer to the affected area twice daily (morning and evening) for up to 7 - 14 days, depending on clinical response.
Application tips:
Wash and gently pat the skin dry before use.
Use a clean fingertip or a disposable applicator; avoid contaminating the tube opening.
Do not cover the treated area with occlusive dressings unless advised by a clinician.
Special populations:
In elderly patients, limit the duration to the shortest effective period, typically 7 days.
For pregnant or lactating women, the physician may prescribe a lower-strength corticosteroid or an alternative therapy.
Missed dose: Apply as soon as remembered unless the next scheduled dose is near; do not double the amount.
Overdose: Excessive application may lead to systemic corticosteroid effects such as mood changes, increased blood glucose, or adrenal suppression. Seek medical attention if large areas have been treated unintentionally.
Discontinuation: Abrupt cessation after prolonged use may cause rebound inflammation. If treatment exceeds 2 weeks, a tapering schedule (e.g., every other day) may be recommended by the prescriber.
Routine laboratory monitoring is not required for short-term topical therapy. However, patients should:
This article provides educational information about Fusiderm B and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, you may transport Fusiderm B in your carry-on luggage, but keep the tube in its original packaging and ensure it remains within the allowed liquid volume (usually 100 ml). Some countries may require a prescription copy for inspection, so carry a brief note from your doctor if possible.
Fusiderm B is typically supplied in a white, opaque tube with a flip-top cap. The tube may bear a embossing or printed batch number and expiry date; these identifiers help pharmacists verify product authenticity.
Topical fusidic acid and betamethasone are not listed on the World Anti-Doping Agency (WADA) prohibited list. However, excessive application on large skin areas could potentially lead to detectable systemic levels of corticosteroids, which may be scrutinised in some sports. Athletes should disclose use to their medical team.
The medication should be applied to clean, dry skin before any dressing is placed. Covering the area with an occlusive bandage can increase drug absorption and the risk of side effects, so this practice is generally discouraged unless specifically instructed.
Both products combine a corticosteroid with an antibiotic, but the antibiotic component differs: Fusiderm B uses fusidic acid, whereas Betnovate-SC contains neomycin and bacitracin. Choice of product depends on the suspected bacterial spectrum and patient tolerance.
Immediately flush the eye(s) with plenty of clean water or saline for at least 15 minutes and seek medical attention promptly. The formulation is not intended for ocular use and may cause irritation.
Prolonged or inappropriate use of any antibiotic can promote resistance. Fusidic Acid resistance has been reported in Staphylococcus species when used for extended periods. Adhering to the prescribed duration minimizes this risk.
Yes, applying a fragrance-free, non-comedogenic moisturizer after Fusiderm B has been absorbed (typically 10-15 minutes) can help alleviate dryness and support barrier repair. Avoid moisturisers containing alcohol or strong irritants.
Expired topical medicines should be disposed of as hazardous pharmaceutical waste. Many local pharmacies in Hong Kong provide a take-back service; alternatively, follow the “reverse-pharmacy” guidelines published by the Department of Health.
In Hong Kong, generic versions containing the same concentrations of fusidic acid and betamethasone may be available under different brand names. Discuss with your pharmacist or physician for possible alternatives that meet the same therapeutic needs.
